萨特利珠单抗在视神经脊髓炎谱系疾病治疗中的研究现状  

Research status of suterizumab in the treatment of neuromyelitis optica spectrum disorders

作　　者：白云飞 高紫谊 岳月红[3] 肖向建[3,4] BAI Yun-fei;GAO Zi-yi;YUE Yue-hong;XIAO Xiang-jian(Graduate School,North China University of Science and Technology,Tangshan 063000,Hebei Province,China;Graduate School,Hebei North University,Zhangjiakou 075000,Hebei Province,China;A Department of Neurology,Hebei Provincial People's Hospital,Shijiazhuang 050000,Hebei Province,China;Hebei Key Laboratory of Brain Network and Cognitive Disorders,Hebei Provincial People's Hospital,Shijiazhuang 050000,Hebei Province,China)

机构地区：[1]华北理工大学研究生院,河北唐山063000 [2]河北北方学院研究生院,河北张家口075000 [3]河北省人民医院神经内一科,河北石家庄050000 [4]河北省人民医院河北省脑网络与认知障碍疾病重点实验室,河北石家庄050000

出　　处：《中国临床药理学杂志》2024年第22期3348-3352,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：视神经脊髓炎谱系疾病(NMOSD)会反复发作,且遗留明显的神经功能缺损,对患者的生活质量造成严重的影响。近年来,白细胞介素-6受体抑制药萨特利珠单抗在治疗NMOSD方面表现突出,其可以有效降低复发率,且药物不良反应较少。本文现将萨特利珠单抗在治疗NMOSD的机制以及疗效和药物不良反应等情况进行综述。Neuromyelitis optica spectrum disorders(NMOSD)is a recurrent disease with significant neurological deficits,which can seriously affect the quality of life of patients.In recent years,the interleukin-6 receptor suppressor suterizumab has shown outstanding performance in the treatment of NMOSD,which can effectively reduce the recurrence rate and have fewer adverse drug reactions.This article reviews the mechanism,efficacy and adverse drug reactions of suterizumab in the treatment of NMOSD.

关 键 词：萨特利珠单抗 视神经脊髓炎谱系疾病 白细胞介素-6受体抑制药 有效性 安全性 

分 类 号：R97[医药卫生—药品]